Skip to main content
Rheumatoid Arthritis Panel: EULAR 2025

Panelists Drs. Mrinalini Dey, Janet Pope, Jonathan Kay and Jack Cush review RA

Dr. John Cush RheumNow

1 year 3 months ago
Rheumatoid Arthritis Panel: EULAR 2025 Panelists Drs. Mrinalini Dey, Janet Pope, Jonathan Kay and Jack Cush review RA studies and sessions presented at the 2025 EULAR meeting in Barcelona, Spain. Abstracts discussed: OP0004; OP0105; LB0006; OP0327; OP0330; OP0232; 0P0190. https://t.co/hmosUKOgTt
IL-17 inhibitors - Long-term Extensions and Uveitis

Dr. Peter Nash offers his perspective on data presented at the 202

Dr. John Cush RheumNow

1 year 3 months ago
IL-17 inhibitors - Long-term Extensions and Uveitis Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona. https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj
FDA adds new warning for "myocarditis" to the Pfizer and Moderna COVID-19 vaccines (prev mainly assoc w/ Moderna) - ris

Dr. John Cush RheumNow

1 year 3 months ago
FDA adds new warning for "myocarditis" to the Pfizer and Moderna COVID-19 vaccines (prev mainly assoc w/ Moderna) - risk is 8 per 1 million people for those on 2023-2024 COVID shots, most common in males ages 12 to 24. Generally good outcomes seen. https://t.co/QZbTRaKGH1 https://t.co/1cAUw73eqF
Jekyll and Hyde: which RA-ILD is it?

Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in B

Dr. John Cush RheumNow

1 year 3 months ago
Jekyll and Hyde: which RA-ILD is it? Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/oH9nXaKRDz https://t.co/iUAJk2Q856
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Prospective KORAIL study of 138 RA pts w/ ILD on chest CT -60% had UIP ILD. After F/U of 2.9 yrs, 35% had RA-ILD progres

Dr. John Cush RheumNow

1 year 3 months ago
Prospective KORAIL study of 138 RA pts w/ ILD on chest CT -60% had UIP ILD. After F/U of 2.9 yrs, 35% had RA-ILD progression. Baseline predictors of progression = UIP, ILD >10 %, DLCO %pred, CCP+, KL-6 levels, RA Dz activity. Useful to ID high-risk RA-ILD pts.
Aortic aneurysms w/ GCA. TriNetX study of 7,294 Bx-proven GCA vs 265,948 controls w/ tension HA. GCA had signif higher

Dr. John Cush RheumNow

1 year 3 months ago
Aortic aneurysms w/ GCA. TriNetX study of 7,294 Bx-proven GCA vs 265,948 controls w/ tension HA. GCA had signif higher 5-yr risk of aortic aneurysms (3.59%; aHR 1.98), including thoracic thoracoabdominal & abdominal. Carotid A stenosis also incr in GCA (aHR 1.59) https://t.co/15fwlHa0FG
ARD's Impact Factor
  • EULAR
Annals of the Rheumatic Diseases (ARD) is the official journal of EULAR –The European Alliance of Associations for Rheumatology. An international peer-reviewed publication committed to promoting the highest standards of scientific exchange and education.
There's an App for That (and it works): the AXIA RCT

Dr. Aurelie Najm reports on abstract LB0002 presented at the EULAR

Dr. John Cush RheumNow

1 year 3 months ago
There's an App for That (and it works): the AXIA RCT Dr. Aurelie Najm reports on abstract LB0002 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/IRZ1L7BqLW https://t.co/Av2vVheShE
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

Dr. John Cush RheumNow

1 year 3 months ago
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/ppuzIB4iRf
What we need in very early arthritis

It's easy to think that in our current world that we've done it all for rheumatoid

Dr. John Cush RheumNow

1 year 3 months ago
What we need in very early arthritis It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all https://t.co/v8T3JQwuhM
×